A database of FDA approved therapeutic peptides and proteins
ID1753 | ThPPIDTh1181 | NameFilgrastim-sndz | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIc | DiseaseCancer | BrandZarxio | CompanySandoz Inc | Physical AppearanceSolution | Route of AdministartionIntravenous; Subcutaneous | CategoryNA | TargetNA |
ID1798 | ThPPIDTh1192 | NameUstekinumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseInfectious Disease | BrandStelara | CompanyJanssen Biotech, Inc. | Physical AppearanceSolution fro Injection | Route of AdministartionSubcutaneous | CategoryDeramtologic agent, Immunosuppressive agent, antineoplastic agent | TargetInterleukin-12 subunit beta |
ID1812 | ThPPIDTh1203 | NamePeginterferon beta-1a | Peptide SequenceNA Full view | Length0 | Functional ClassificationIa | DiseaseNeurological Disorder | BrandPlegridy | CompanyBiogen Canada Inc | Physical AppearanceSterile Solution | Route of AdministartionSubcutaneous | CategoryNA | Target |
ID1817 | ThPPIDTh1208 | NameMetreleptin | Peptide SequenceMVPIQKVQDDTKTLIKTIVT Full view | Length147 | Functional ClassificationIb | DiseaseAdjunct therapy | BrandMyalept | CompanyAmylin Pharmaceuticals, LLC | Physical AppearanceLyophilized Powder for Solution | Route of AdministartionSubcutaneous | Category | TargetLeptin receptor |
ID1819 | ThPPIDTh1210 | NameMepolizumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseRespiratory Disorder | BrandNucala | CompanyGlaxosmithkline Inc | Physical AppearanceLyophilized Powder | Route of AdministartionSubcutaneous | CategoryAntineoplastic and Immunomodulating Agents, Immunosuppressive Agents, Interleukin Inhibitors | TargetInterleukin-5 |
ID1820 | ThPPIDTh1211 | NameIxekizumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIc | DiseaseInfectious Disease | BrandTaltz | CompanyEli lilly | Physical AppearanceSterile, preservative free, clear and colorless to slightly yellow Solution | Route of AdministartionSubcutaneous | CategoryNA | TargetNA |
ID1821 | ThPPIDTh1212 | NameInsulin Pork | Peptide SequenceA chain GIVEQCCTSICS Full view | Length68 | Functional ClassificationIa | DiseaseMetabolic Disorders | BrandIletin II | CompanyLilly | Physical Appearancesterile suspension | Route of AdministartionSubcutaneous | CategoryHypoglycemic Agents, Antidiabetic Agents | TargetInsulin receptor, Insulin-like growth factor 1 receptor, Insulin-degrading enzyme, HLA class II histocompatibility antigen, DQ alpha 2 chain, HLA class II histocompatibility antigen, DQ beta 1 chain, Retinoblastoma-associated protein, Cathepsin D, Carboxypeptidase E, Neuroendocrine convertase 2, Neuroendocrine convertase 1, Protein NOV homolog, Low-density lipoprotein receptor-related protein 2, Insulin-like growth factor-binding protein 7, Synaptotagmin-like protein 4, Cytochrome P450 1A2 |
ID1822 | ThPPIDTh1213 | NameInsulin Degludec | Peptide SequenceInsulin degludec dif Full view | Length0 | Functional ClassificationIa | DiseaseMetabolic Disorders | BrandTresiba | CompanyNovo Nordisk | Physical Appearancesterile, aqueous, clear, and colorless Solution | Route of AdministartionSubcutaneous | CategoryNA | TargetNA |
ID1830 | ThPPIDTh1220 | NameBrodalumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIa | DiseaseImmunological Disorders | BrandSiliq | CompanyNA | Physical Appearancesterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution | Route of AdministartionSubcutaneous | CategoryAntineoplastic and Immunomodulating Agents | Target Interleukin 17 receptor A |
ID1832 | ThPPIDTh1222 | NameCanakinumab | Peptide SequenceH-GAMMA-1 Chain: QVQ Full view | Length842 | Functional ClassificationIIa | DiseaseImmunological Disorders | BrandIlaris | CompanyNovartis | Physical AppearanceLyphilized powder | Route of AdministartionSubcutaneous | CategoryAntineoplastic and Immunomodulating Agents | TargetInterleukin-1 beta |
ID1833 | ThPPIDTh1223 | NameChorionic Gonadotropin (Human) | Peptide SequenceAlpha Chain: APDVQDC Full view | Length237 | Functional ClassificationIa | DiseaseHormonal Disorders | BrandOvidrel | CompanyEmd Serono | Physical AppearanceInjection, solution | Route of AdministartionSubcutaneous | CategoryHormones | TargetLutropin-choriogonadotropic hormone receptor |
ID1834 | ThPPIDTh1223 | NameChorionic Gonadotropin (Human) | Peptide SequenceAlpha Chain: APDVQDC Full view | Length237 | Functional ClassificationIa | DiseaseHormonal Disorders | BrandPregnyl | CompanyPhysicians Total Care, Inc. | Physical AppearanceInjection, Solution | Route of AdministartionIntramuscular, Subcutaneous | CategoryHormones | TargetLutropin-choriogonadotropic hormone receptor |
ID1835 | ThPPIDTh1224 | NameChorionic Gonadotropin (Recombinant) | Peptide SequenceAlpha chain : APDVQD Full view | Length237 | Functional ClassificationIa | DiseaseHormonal Disorders | BrandOvitrelle | CompanyMerck Serono Europe Limited | Physical Appearancepowder and solvent to be made up into a solution | Route of AdministartionSubcutaneous | CategoryHormones | TargetLutropin-choriogonadotropic hormone receptor, Follicle-stimulating hormone receptor |
ID1844 | ThPPIDTh1232 | NameLenograstim | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseImmunological Disorders | BrandGranocyte | CompanyNA | Physical AppearanceSolid | Route of AdministartionSubcutaneous or Intravenous | CategoryAntineoplastic and Immunomodulating Agents | TargetGranulocyte colony-stimulating factor receptor |
ID1849 | ThPPIDTh1237 | NameSomatropin recombinant | Peptide SequenceFPTIPLSRLFDNAMLRAHRL Full view | Length191 | Functional ClassificationIb | DiseaseHormonal Disorders | BrandBioTropin | CompanyBiotech General | Physical AppearancePowder and Solvent for Solution | Route of AdministartionSubcutaneous | CategoryHormones, Hormone Substitutes, and Hormone Antagonists | TargetGrowth hormone receptor, Prolactin receptor |
ID1850 | ThPPIDTh1237 | NameSomatropin recombinant | Peptide SequenceFPTIPLSRLFDNAMLRAHRL Full view | Length191 | Functional ClassificationIb | DiseaseHormonal Disorders | BrandNutropinAQ | CompanyGenentech Inc. | Physical AppearanceSterile liquid | Route of AdministartionSubcutaneous | CategoryHormones, Hormone Substitutes, and Hormone Antagonists | TargetGrowth hormone receptor, Prolactin receptor |